Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Bellevue, WA
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Bellevue, WA
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Richland, WA
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Richland, WA
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Spokane, WA
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated:  5/2/2016
mi
from
Banfield,
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Status: Enrolling
Updated: 5/2/2016
mi
from
Banfield,
Click here to add this to my saved trials
First in Man Study of Safety, Tolerability and PK Profile of RBP-7000
An Open Label, Single Center, Single Dose, Phase 1, First in Man Study of the Safety, Tolerability and Pharmacokinetic Profile of RBP-7000
Status: Enrolling
Updated:  5/5/2016
CRI Worldwide, LLC
mi
from
Willingboro, NJ
First in Man Study of Safety, Tolerability and PK Profile of RBP-7000
An Open Label, Single Center, Single Dose, Phase 1, First in Man Study of the Safety, Tolerability and Pharmacokinetic Profile of RBP-7000
Status: Enrolling
Updated: 5/5/2016
CRI Worldwide, LLC
mi
from
Willingboro, NJ
Click here to add this to my saved trials
A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Patients With Schizophrenia and Schizoaffective Disorder
A Randomized, Double-blind, Placebo-controlled Parallel Arm Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Schizophrenia and Schizoaffective Disorder
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Orangeburg, NY
A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Patients With Schizophrenia and Schizoaffective Disorder
A Randomized, Double-blind, Placebo-controlled Parallel Arm Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Schizophrenia and Schizoaffective Disorder
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Orangeburg, NY
Click here to add this to my saved trials
PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations
Demonstration of mGluR5 Overexpression in Amish and Mennonite CNTNAP2 Mutation Carriers
Status: Enrolling
Updated:  6/7/2016
New York State Psychiatric Insitute
mi
from
New York, NY
PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations
Demonstration of mGluR5 Overexpression in Amish and Mennonite CNTNAP2 Mutation Carriers
Status: Enrolling
Updated: 6/7/2016
New York State Psychiatric Insitute
mi
from
New York, NY
Click here to add this to my saved trials
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated:  7/13/2016
Alkermes Study Site
mi
from
Little Rock, AR
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated: 7/13/2016
Alkermes Study Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated:  7/13/2016
Alkermes Study Site
mi
from
Washington,
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated: 7/13/2016
Alkermes Study Site
mi
from
Washington,
Click here to add this to my saved trials
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated:  7/13/2016
Alkermes Investigational Site
mi
from
Hoffman Estates, IL
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated: 7/13/2016
Alkermes Investigational Site
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated:  7/13/2016
Alkermes Investigational Site
mi
from
Garden Grove, CA
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated: 7/13/2016
Alkermes Investigational Site
mi
from
Garden Grove, CA
Click here to add this to my saved trials
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated:  7/13/2016
Alkermes Investigational Site
mi
from
Oakland, CA
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated: 7/13/2016
Alkermes Investigational Site
mi
from
Oakland, CA
Click here to add this to my saved trials
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated:  7/13/2016
Alkermes Investigational Site
mi
from
Oceanside, CA
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated: 7/13/2016
Alkermes Investigational Site
mi
from
Oceanside, CA
Click here to add this to my saved trials
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated:  7/13/2016
Alkermes Investigational Site
mi
from
Orange, CA
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated: 7/13/2016
Alkermes Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated:  7/13/2016
Alkermes Study Site
mi
from
Ft. Lauderdale, FL
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated: 7/13/2016
Alkermes Study Site
mi
from
Ft. Lauderdale, FL
Click here to add this to my saved trials
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated:  7/13/2016
Alkermes Investigational Site
mi
from
Leesburg, FL
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated: 7/13/2016
Alkermes Investigational Site
mi
from
Leesburg, FL
Click here to add this to my saved trials
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated:  7/13/2016
Alkermes Study Site
mi
from
Atlanta, GA
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated: 7/13/2016
Alkermes Study Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated:  7/13/2016
Alkermes Study Site
mi
from
Chicago, IL
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated: 7/13/2016
Alkermes Study Site
mi
from
Chicago, IL
Click here to add this to my saved trials
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated:  7/13/2016
Alkermes Investigational Site
mi
from
Shreveport, LA
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated: 7/13/2016
Alkermes Investigational Site
mi
from
Shreveport, LA
Click here to add this to my saved trials
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated:  7/13/2016
Alkermes Investigational Site
mi
from
Oklahoma City, OK
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated: 7/13/2016
Alkermes Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated:  7/13/2016
Alkermes Investigational Site
mi
from
Dallas, TX
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated: 7/13/2016
Alkermes Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated:  7/13/2016
Alkermes Investigational Site
mi
from
Burgas,
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Status: Enrolling
Updated: 7/13/2016
Alkermes Investigational Site
mi
from
Burgas,
Click here to add this to my saved trials
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  7/13/2016
Alkermes Investigational Site
mi
from
Dallas, TX
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 7/13/2016
Alkermes Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  7/13/2016
Alkermes Study Site
mi
from
Cerritos, CA
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 7/13/2016
Alkermes Study Site
mi
from
Cerritos, CA
Click here to add this to my saved trials
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  7/13/2016
Alkermes Investigational Site
mi
from
Lemon Grove, CA
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 7/13/2016
Alkermes Investigational Site
mi
from
Lemon Grove, CA
Click here to add this to my saved trials
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  7/13/2016
Alkermes Investigational Site
mi
from
Oakland, CA
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 7/13/2016
Alkermes Investigational Site
mi
from
Oakland, CA
Click here to add this to my saved trials
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  7/13/2016
Alkermes Investigational Site
mi
from
Hoffman Estates, IL
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 7/13/2016
Alkermes Investigational Site
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  7/13/2016
Alkermes Investigational Site
mi
from
Marlton, NJ
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 7/13/2016
Alkermes Investigational Site
mi
from
Marlton, NJ
Click here to add this to my saved trials
OnTrack>An Online Role-Playing Game: A Small Business Innovation Research (SBIR) Grant
OnTrack>An Online Role-Playing Game: A Small Business Innovation Research (SBIR) Grant
Status: Enrolling
Updated:  7/26/2016
Center For Social Innovation
mi
from
Needham, MA
OnTrack>An Online Role-Playing Game: A Small Business Innovation Research (SBIR) Grant
OnTrack>An Online Role-Playing Game: A Small Business Innovation Research (SBIR) Grant
Status: Enrolling
Updated: 7/26/2016
Center For Social Innovation
mi
from
Needham, MA
Click here to add this to my saved trials
OnTrack>An Online Role-Playing Game: A Small Business Innovation Research (SBIR) Grant
OnTrack>An Online Role-Playing Game: A Small Business Innovation Research (SBIR) Grant
Status: Enrolling
Updated:  7/26/2016
New York State Psychiatric Institute
mi
from
New York, NY
OnTrack>An Online Role-Playing Game: A Small Business Innovation Research (SBIR) Grant
OnTrack>An Online Role-Playing Game: A Small Business Innovation Research (SBIR) Grant
Status: Enrolling
Updated: 7/26/2016
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Albuquerque, NM
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Dallas, TX
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Little Rock, AR
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Buena Park, CA
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Buena Park, CA
Click here to add this to my saved trials
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Cerritos, CA
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Cerritos, CA
Click here to add this to my saved trials
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Downey, CA
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Downey, CA
Click here to add this to my saved trials
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
La Palma, CA
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
La Palma, CA
Click here to add this to my saved trials
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Pasadena, CA
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Pasadena, CA
Click here to add this to my saved trials
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Pico Rivera, CA
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Pico Rivera, CA
Click here to add this to my saved trials
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Miami, FL
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Marietta, GA
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Marietta, GA
Click here to add this to my saved trials
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Oak Brook, IL
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Oak Brook, IL
Click here to add this to my saved trials
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Iowa City, IA
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Glen Burnie, MD
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Glen Burnie, MD
Click here to add this to my saved trials
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Toms River, NJ
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Toms River, NJ
Click here to add this to my saved trials
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Willingboro, NJ
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Willingboro, NJ
Click here to add this to my saved trials
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Brooklyn, NY
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Fresh Meadows, NY
A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Fresh Meadows, NY
Click here to add this to my saved trials